Clinical Use Of Cb1 Antagonists Sr 141716

The selective CB1 antagonist SR 141716 (rimonabant or Acomplia; Sanofi-Synthelabo), when administered to marijuana smokers, caused weight loss in overweight and obese subjects without causing adverse side effects (118). Based on this and the promising studies on animals (reviewed previously), SR 141716 has been used in randomized, double-blind clinical trials to determine its efficacy in treating obesity and related metabolic complications. Several Phase III clinical trials named RIO (Rimonabant In Obesity) were initiated starting in 2001 and included more than 6600 overweight or obese patients with or without comorbidities who were given SR141716 (5 or 20 mg) or placebo for up to 2 yr (119 - 121). All subjects were on a calorie-restricted diet and underwent a run-in period of diet alone prior to being randomized to drug or placebo conditions.

Spiritual Weight Loss Mentality

Spiritual Weight Loss Mentality

Awesome Ways To Get Over Your Mentality That Keeps you Overweight! This Book Is One Of The Most Valuable Resources In The World When It Comes To Results In Your Slim-down and Health Efforts! Day in day out we keep ourselves absorbed with those matters that matter the most to us. A lot of times, it might be just to survive and bring in some money. In doing so we at times disregard or forget about the extra matters that are essential to balance our lives. They’re even more essential to supply real meaning to our world. You have to pay attention to your wellness.

Get My Free Ebook


Post a comment